164 results for "Default Mode Network"
Changes in music-evoked emotion and ventral striatal functional connectivity after psilocybin therapy for depression
Journal of Psychopharmacology – November 26, 2022
Summary
Psilocybin therapy dramatically enhanced music-evoked pleasure, correlating with reduced anhedonia in 19 patients with treatment-resistant depression. Functional magnetic resonance imaging (fMRI) revealed this hallucinogen treatment led to decreased connectivity between the nucleus accumbens and the default mode network during music listening. Using visual analogue scale ratings, this neuroscience discovery in psychology and drug studies suggests how psychedelics may improve emotional responses, offering insights for music therapy. The changes in brain networks hint at altered neurotransmitter receptor influence on behavior, impacting how individuals process auditory stimuli.
Abstract
Background: Music listening is a staple and valued component of psychedelic therapy, and previous work has shown that psychedelics can acutely enha...
Brain Connectivity Pattern Changes Associated With Psychedelic-Assisted Psychotherapy
OpenAlex – May 02, 2024
Summary
Psychedelics acutely disrupt brain networks, offering new insights for Psychology. Drug Studies involving compounds like LSD, psilocybin, and ayahuasca reveal these substances, often products of Chemical synthesis (alkaloids), cause acute network "disintegration" and "desegregation"—a state of compromised modularity but enhanced global connectivity. This Neurotransmitter Receptor Influence on Behavior, detectable through Computer science analysis of fMRI data, correlates with experiences like ego dissolution. Later, increased default mode network integrity appears. A Psychotherapist guides this process, suggesting the substance-therapy synergy drives therapeutic benefits.
Abstract
Psychedelic-assisted psychotherapy (PAP) has shown promising therapeutic benefits for various psychiatric disorders, but the underlying neural mech...
Neurophysiological features of dream recall and the phenomenology of dreams: Auditory stimulation impacts dream experiences.
Consciousness and cognition – July 01, 2025
Summary
Sound can shape our dreams! Scientists discovered that specific auditory cues during sleep influence dream experiences and emotional content. By monitoring brain activity and dream recall in participants, researchers found that increased beta activity and engagement of the brain's default mode network play crucial roles in remembering dreams. Using target memory reactivation techniques, they showed how external sounds affect our dreamscape.
Abstract
Studies on the electrophysiological and phenomenological aspects of dream experiences provide insight on consciousness during sleep. Whole night po...
Pretreatment Brain White Matter Integrity Associated With Neuropathic Pain Relief and Changes in Temporal Summation of Pain Following Ketamine.
The journal of pain – September 01, 2024
Summary
Brain structure may predict how well ketamine treats chronic nerve pain. New research shows that the integrity of white matter pathways, particularly in the default mode network and pain control regions like the periaqueductal gray, correlates with how effectively ketamine reduces neuropathic pain and pain sensitivity in patients.
Abstract
Neuropathic pain (NP) is a prevalent condition often associated with heightened pain responsiveness suggestive of central sensitization. Neuroimagi...
Human Cortical Serotonin 2A Receptor Occupancy by Psilocybin Measured Using [11C]MDL 100,907 Dynamic PET and a Resting-State fMRI-Based Brain Parcellation
Frontiers in Neuroergonomics – January 20, 2022
Summary
Psilocybin, a potent hallucinogen, significantly engages brain serotonin 5-HT receptors. Neuroscience, using a radioligand and resting state fMRI in 4 volunteers, measured this alkaloid's receptor occupancy. This agonist achieved an average 39.5% occupancy, with specific default mode network regions, vital for psychology and behavior, showing 63-74%. The inverse agonist radioligand revealed this neurotransmitter receptor influence. Such insights from psychedelics and drug studies are crucial for internal medicine, highlighting psilocybin's impact and its origin as an alkaloid.
Abstract
Psilocybin (a serotonin 2A, or 5-HT 2A , receptor agonist) has shown preliminary efficacy as a treatment for mood and substance use disorders. The ...
Psilocybin reduces low frequency oscillatory power and neuronal phase-locking in the anterior cingulate cortex of awake rodents
Scientific Reports – July 26, 2022
Summary
Psilocybin, a potent hallucinogen, profoundly alters brain activity, offering insights for psychology and medicine. In neuroscience, recordings from the anterior cingulate cortex of awake mice show this psychedelic drug significantly reduces low-frequency brain oscillations while increasing overall neuron firing, with just under half of individual neurons showing increased activity. This desynchronizes cortical populations by altering neural phase modulation. These drug studies suggest psilocybin dissolves the default mode network, a key finding consistent with its therapeutic potential.
Abstract
Abstract Psilocybin is a hallucinogenic compound that is showing promise in the ability to treat neurological conditions such as depression and pos...
Acute Effects of Psilocybin and Salvinorin-A on Functional Connectivity
Proceedings on CD-ROM - International Society for Magnetic Resonance in Medicine. Scientific Meeting and Exhibition/Proceedings of the International Society for Magnetic Resonance in Medicine, Scientific Meeting and Exhibition – August 14, 2024
Summary
Neuroscience reveals how two distinct hallucinogens, Psilocybin and Salvinorin-A, profoundly alter brain communication. Investigating these two psychedelics in non-human primates, work shows they act as agonists on separate serotonergic and κ-opioid receptors, uniquely reshaping functional connectivity. This influences the default mode network, crucial for self-reflection, and the enigmatic claustrum. Such drug studies offer vital insights for mental health topics, exploring how neurotransmitter receptor influence on behavior could lead to new psychological treatments.
Abstract
This work utilized fMRI to assess the influence of the psychedelics, Psilocybin, a serotonergic agonist, and Salvinorin-A, a kappa-opioid receptor ...
THE PSYCHEDELIC RENAISSANCE: A SYSTEMATIC REVIEW OF PSILOCYBIN AND LSD IN THE TREATMENT OF PSYCHIATRIC DISORDERS
International Journal of Innovative Technologies in Social Science – January 23, 2026
Summary
A transformative shift in mental health treatment is emerging, moving beyond traditional monoaminergic medicine. Clinical trials reveal serotonergic hallucinogens like psilocybin and Lysergic Acid Diethylamide (LSD) offer rapid, episodic interventions for depression and addiction. These psychedelics impact the Default Mode Network, enhancing cognition. Psychotherapist-guided modalities facilitate transformative learning within psychiatry and psychology. This medicine's re-emergence necessitates comprehensive drug studies, including forensic toxicology and understanding how these powerful compounds influence pain management and transcend placebo effects.
Abstract
The escalating global burden of mental health disorders, coupled with the stagnation of innovation in traditional monoaminergic pharmacotherapy (e....
Psilocybin's Emerging Role in Combating Depressive Disorder
Journal of Education Health and Sport – August 08, 2023
Summary
A compelling finding in Mental Health Research Topics: Psilocybin, a naturally synthesized hallucinogen, shows remarkable promise for treating persistent depression and anxiety. Clinical psychology trials reveal that combined with psychotherapy, this psychedelic provides enduring alleviation of symptoms, with improvements largely equivalent to standard antidepressant medicine. Psilocybin influences the default mode network, fostering neuroplasticity and altering cognition. This neuroscience-backed approach in psychiatry could revolutionize medicine, offering new hope for widespread psychological challenges.
Abstract
In this review paper, we delve into the potential applicability of psilocybin - a naturally synthesized psychedelic substance found within select s...
Neural mechanisms underlying psilocybin’s therapeutic potential – the need for preclinical in vivo electrophysiology
Journal of Psychopharmacology – May 30, 2022
Summary
Psilocybin, a potent natural hallucinogen, shows immense promise for treating brain disorders. While Neuroscience and Psychology explore its profound effects on consciousness and cognition, the precise neurophysiology remains complex. Neuroimaging reveals its influence on the prefrontal cortex and default mode network, but how this psychedelic compound, an alkaloid, specifically modulates biological neural networks and neurotransmitter receptors is still being elucidated. Electrophysiology is crucial for clarifying these mechanisms, advancing drug studies, and unlocking its therapeutic potential.
Abstract
Psilocybin is a naturally occurring psychedelic compound with profound perception-, emotion- and cognition-altering properties and great potential ...
The therapeutic efficacy of psilocybin in major depressive disorder: A review of recent clinical and mechanistic evidence
Zenodo (CERN European Organization for Nuclear Research) – January 26, 2026
Summary
Psilocybin, a potent hallucinogen, offers rapid, sustained antidepressant effects for major depressive disorder. Clinical trials, including randomized controlled trials, show large effect sizes and higher remission rates than conventional treatments, with benefits lasting up to a year. Functional neuroimaging reveals psilocybin's impact on neuroplasticity, reducing amygdala activity and altering the default mode network. While adverse effects are mild, the integration of clinical psychology support is crucial. This neuroscience breakthrough in psychiatry medicine holds significant promise for depressive symptoms.
Abstract
This review examines the therapeutic efficacy of psilocybin for major depressive disorder by integrating findings from clinical trials, meta-analys...
Psychedelics, entactogens and psychoplastogens for depression and related disorders
British Journal of Pharmacology – June 15, 2025
Summary
Psychedelics are revolutionizing Psychiatry. Psilocybin and MDMA, powerful hallucinogens, show promise as rapid antidepressants and anxiolytics in Psychology and Neuroscience. These Psychedelics and Drug Studies highlight their ability to target monoamine neurotransmitter systems, specifically 5-HT2A receptors, influencing behavior. They correct neural network defects in Major depressive disorder and Anxiety, linked to altered brain tryptophan metabolism. Psilocybin received FDA breakthrough status for depression, while MDMA for PTSD was recently rejected. This offers new hope for severe mental health conditions.
Abstract
Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin...
Psilocybin-induced changes in brain network integrity and segregation correlate with plasma psilocin level and psychedelic experience.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology – September 01, 2021
Summary
No Summary
Abstract
The emerging novel therapeutic psilocybin produces psychedelic effects via engagement of cerebral serotonergic targets by psilocin (active metaboli...
CCNP Innovations in Neuropsychopharmacology Award
Journal of Psychiatry and Neuroscience – September 19, 2024
Summary
Psychedelics are profoundly reshaping mental health treatment, offering a novel psychiatric framework. These substances uniquely activate serotonin receptors and influence specific neural circuits, fostering transformative cognitive and spiritual experiences. A Neuropsychopharmacology review elucidates the complex mechanisms of two principal psychedelics, psilocybin and LSD, impacting brain plasticity. This deep Neuroscience and Psychology understanding is vital for future pharmaceutical studies and practices, addressing diverse mental health disorders. Such insights could even extend to conditions like Attention Deficit Hyperactivity Disorder, integrating brain, mind, and spirituality.
Abstract
For 3000 years, psychedelics have been used in religious contexts to enhance spiritual thinking, well-being, and a sense of community. In the last ...
The evolution of N, N-Dimethyltryptamine: from metabolic pathways to brain connectivity.
Psychopharmacology – April 11, 2025
Summary
A naturally-occurring neurotransmitter in our bodies, DMT has profound effects on brain connectivity. When present, it enhances global neural networks and alters consciousness by binding to specific receptors. Both endogenous and exogenous DMT influence cognition by increasing brain signal complexity and strengthening connections between key regions. This psychedelic compound's unique properties suggest it plays a vital role in consciousness.
Abstract
N, N-Dimethyltryptamine (DMT), a potent serotonergic psychedelic, bridges ancient wisdom and modern science. The mechanisms underlying its powerful...
Acute Effects of Hallucinogens on Functional Connectivity: Psilocybin and Salvinorin-A
ACS Chemical Neuroscience – June 25, 2024
Summary
A compelling finding in **Drug Studies** reveals that **Hallucinogens**, including **Psilocybin** and Salvinorin-A, dramatically reshape brain connectivity. Despite their distinct **Neurotransmitter Receptor Influence on Behavior**—one a classical **Psychedelic**, the other a kappa-opioid agonist—both acutely desynchronize the brain's default mode network. Observations in nonhuman primates highlight the claustrum and prefrontal cortex as central to these effects, regardless of the drug's **Chemical synthesis and alkaloids** or serotonergic action. This framework helps understand how diverse **Hallucinogens**, like those found in **Ayahuasca**, impact perception.
Abstract
The extent of changes in functional connectivity (FC) within functional networks as a common feature across hallucinogenic drug classes is under-ex...
Antidepressant and anxiolytic effects of activating 5HT2A receptors in the anterior cingulate cortex and the theoretical mechanisms underlying them - A scoping review of available literature.
Brain research – January 01, 2025
Summary
No Summary
Abstract
Psychedelic drugs that activate the 5HT2A receptor have long been the target of extensive clinical research, particularly in models of psychiatric ...
Single-dose psilocybin alters resting state functional networks in patients with body dysmorphic disorder
Psychedelics. – September 24, 2024
Summary
Psilocybin shows promise for Body dysmorphic disorder, a severe psychiatric condition. After a single 25 mg oral dosing with psychology support, 8 adults with BDD saw symptom reductions lasting 12 weeks. Functional magnetic resonance imaging (fMRI) revealed that increased resting state fMRI connectivity within brain networks, including connections to the Default mode network's Precuneus and the Insula, predicted this improvement. These findings, relevant to Medicine, Psychiatry, and Body Image and Dysmorphia Studies, highlight psilocybin's potential in Psychosomatic Disorders and Their Treatments, advancing Psychedelics and Drug Studies.
Abstract
Body dysmorphic disorder (BDD) is a severe psychiatric condition characterized by preoccupation with perceived flaws in one's appearance, which the...
Large-scale brain connectivity changes following the administration of lysergic acid diethylamide, d-amphetamine, and 3,4-methylenedioxyamphetamine.
Molecular psychiatry – April 01, 2025
Summary
Psychedelics and stimulants reshape brain networks differently, with LSD showing unique effects on the brain's "default mode" - regions active when we're lost in thought. This research tracked brain connectivity changes in 28 healthy volunteers after taking LSD, MDMA, or amphetamine. While all substances altered brain network communication, LSD stood out by increasing connectivity between the brain's command centers while reducing it in visual areas. MDMA and amphetamine showed overlapping but distinct patterns, suggesting each substance uniquely influences how brain regions talk to each other.
Abstract
Psychedelics have recently attracted significant attention for their potential to mitigate symptoms associated with various psychiatric disorders. ...
Neural correlates of treatment response to ketamine for treatment-resistant depression: A systematic review of MRI-based studies.
Psychiatry research – October 01, 2024
Summary
Ketamine offers new hope for people with severe depression who haven't responded to traditional treatments. Brain imaging reveals that this medication works by targeting specific neural networks linked to mood, pleasure, and negative thought patterns. Using magnetic resonance imaging, researchers found ketamine reduces anhedonia and suicidal thoughts by activating key brain regions involved in emotion processing. The treatment shows particular promise in reducing thought rumination in treatment-resistant depression.
Abstract
Treatment-resistant depression (TRD) is defined as patients diagnosed with depression having a history of failure with different antidepressants wi...
What fMRI studies say about the nature of the psychedelic effect: a scoping review
Frontiers in Neuroscience – July 01, 2025
Summary
Psychedelics like psilocybin profoundly reshape brain function, showing promise for mental health. A comprehensive review of dozens of functional magnetic resonance imaging (fMRI) studies in neuroscience reveals consistent patterns. These serotonergic compounds induce a "de-differentiation" of brain networks, notably impacting the default mode network, thalamus, and amygdala. This insight from cognitive psychology, leveraging diverse fMRI approaches, highlights ego dissolution's importance, advancing our understanding of how these serotonergic substances influence behavior in drug studies through biochemical analysis.
Abstract
Research on psychedelic drugs, such as psilocybin, LSD or DMT, is a burgeoning field, with an increasing number of studies showing their promise in...
Psilocybin acutely alters the functional connectivity of the claustrum with brain networks that support perception, memory, and attention.
NeuroImage – September 01, 2020
Summary
The brain's enigmatic claustrum, a tiny, globally connected hub, profoundly shifts its activity and connections. Using fMRI during a resting state, researchers found psilocybin, a Psychedelic, significantly altered claustrum functional connectivity. Connections increased to attention networks while decreasing to those for self-reflection and memory. These profound shifts were directly tied to the Serotonin 2A receptor. This pioneering work is the first to show Serotonin 2A receptor signaling influences claustrum function, highlighting its vital role in Psychedelics' subjective and potential therapeutic benefits.
Abstract
Psychedelic drugs, including the serotonin 2a (5-HT2A) receptor partial agonist psilocybin, are receiving renewed attention for their possible effi...
Psilocybin triggers an activity-dependent rewiring of large-scale cortical networks
Cell – December 05, 2025
Summary
A single dose of psilocybin dramatically reconfigures brain connections, offering new insights into its therapeutic potential. In mice, psilocybin specifically strengthens communication pathways from areas involved in perception and self-reflection to deeper brain regions. Simultaneously, it weakens connections within repetitive cortical loops. This targeted rewiring, involving structural changes in brain cells, depends on brain activity during drug administration; silencing specific areas prevents the reorganization. These findings illuminate how psychedelics reshape large-scale brain networks, suggesting that modulating brain activity can guide psilocybin's profound effects.
Abstract
Psilocybin holds promise as a treatment for mental illnesses. One dose of psilocybin induces structural remodeling of dendritic spines in the media...
Psilocybin-Assisted Therapy: A Review of a Novel Treatment for Psychiatric Disorders
Journal of Psychoactive Drugs – May 08, 2017
Summary
The hallucinogen psilocybin shows compelling promise for psychiatry. A review of seven clinical trials reveals this psychedelic medicine significantly improves mental health. Participants experienced large effect sizes for reduced anxiety and depression symptoms. Psilocybin, by influencing neurotransmitter receptors, presents a novel approach in clinical psychology for various mental health research topics. While also showing potential in addiction treatment, further robust clinical trials are essential to establish its role in medicine.
Abstract
Recent research suggests that functional connectivity changes may be involved in the pathophysiology of psychiatric disorders. Hyperconnectivity in...
Alterations in brain network connectivity and subjective experience induced by psychedelics: a scoping review
Frontiers in Psychiatry – May 14, 2024
Summary
Profound subjective experiences from psychedelics like psilocybin and LSD are directly linked to specific changes in brain functional connectivity. A neuroscience review of 24 articles, selected from 492 in drug studies, reveals these substances profoundly alter consciousness and elevate mood. Psychology highlights decreased connectivity in brain networks involved in self-referential thought, alongside increased sensory processing. Such neurophysiological shifts offer a potential neural mechanism for reported mystical experiences, informing medicine's exploration of these compounds' therapeutic applications.
Abstract
Intense interest surrounds current research on psychedelics, particularly regarding their potential in treating mental health disorders. Various st...
Serotonergic psychedelics for depression: What do we know about neurobiological mechanisms of action?
Frontiers in Psychiatry – February 10, 2023
Summary
Serotonergic psychedelics demonstrate large effect sizes in treating major depressive disorder, offering new hope in Psychiatry and Medicine. Their rapid antidepressant action involves potent 5HT2A neurotransmitter receptor influence on behavior, leading to rapid receptor downregulation. This Neuroscience perspective suggests these compounds, often from chemical synthesis and alkaloids, may also impact brain-derived neurotrophic factor. Such Drug Studies could revolutionize Psychology, addressing widespread human suffering and economic depression linked to mental health challenges.
Abstract
Introduction Current treatment options for major depressive disorder (MDD) have limited efficacy and are associated with adverse effects. Recent st...
Mindfulness Meditation and Network Neuroscience: Review, Synthesis, and Future Directions.
Biological psychiatry. Cognitive neuroscience and neuroimaging – April 01, 2025
Summary
No Summary
Abstract
Network neuroscience is an interdisciplinary field, which can be used to understand the brain by examining the connections between its constituent ...
The Therapeutic Potential of Psychedelics on Reducing Rumination: A Mini-Review.
Psychedelic medicine (New Rochelle, N.Y.) – September 01, 2024
Summary
No Summary
Abstract
Rumination is a well-established risk factor for the onset and maintenance of depression and anxiety and is associated with various other forms of ...
Psychedelic-assisted Therapy as a Promising Treatment for Irritable Bowel Syndrome.
Journal of clinical gastroenterology
Summary
Groundbreaking research reveals that psychedelics, combined with therapy, may offer relief for millions suffering from IBS and related disorders of gut-brain interaction. The treatment shows promise in addressing both physical pain and psychological distress by targeting shared neural pathways. Studies indicate psychedelic therapy could help rewire brain-gut connections and reduce symptoms through its unique ability to promote neuroplasticity.
Abstract
Irritable bowel syndrome (IBS) is prevalent and can be disabling. Many patients remain symptomatic despite behavioral and medical therapies. Psyche...
Mushrooms, Microdosing, and Mental Illness: The Effect of Psilocybin on Neurotransmitters, Neuroinflammation, and Neuroplasticity.
Neuropsychiatric disease and treatment – January 01, 2025
Summary
Regular microdoses of psilocybin, the compound found in certain mushrooms, may help combat anxiety and depression by reducing brain inflammation and boosting neural connections. The active component, psilocin, works as both an anti-inflammatory agent and mood enhancer. Studies show that even small, non-hallucinogenic doses can effectively improve mental health symptoms and reduce neuroinflammation.
Abstract
The incidence of mental health disorders is increasing worldwide. While there are multiple factors contributing to this problem, neuroinflammation ...
Current Understanding on Psilocybin for Major Depressive Disorder: A Review Focusing on Clinical Trials
Clinical Psychopharmacology and Neuroscience – November 30, 2023
Summary
Psilocybin, a potent hallucinogen, shows remarkable antidepressant potential for major depressive disorder and treatment-resistant depression. Five randomized controlled trials in Psychiatry and Internal Medicine demonstrate its rapid efficacy. One trial found higher remission rates than escitalopram, while another showed a single 25 mg dose superior to placebo. Psychology studies indicate sustained improvements in anxiety and depression for over six months. This pharmacology, a key area in Psychedelics and Drug Studies, offers a new frontier for mental health treatment.
Abstract
Previous studies suggested effectiveness of psilocybin in the field of mental health. FDA designated psilocybin as a "breakthrough therapy" for the...
Local activity alterations in autism spectrum disorder correlate with neurotransmitter properties and ketamine induced brain changes.
medRxiv : the preprint server for health sciences – October 21, 2024
Summary
Brain activity patterns in autism mirror effects of ketamine, revealing key insights into neurotransmitter imbalances. Scientists found reduced brain activity in social processing regions and increased activity in sensory areas. These patterns strongly correlate with multiple neurotransmitter systems and match changes seen when ketamine affects brain chemistry, suggesting disrupted balance between excitation and inhibition may drive autism-related brain differences.
Abstract
Autism spectrum disorder (ASD) is a neurodevelopmental condition associated with altered resting-state brain function. An increased excitation-inhi...
Functional activity and connectivity signatures of ketamine and lamotrigine during negative emotional processing: a double-blind randomized controlled fMRI study.
Translational psychiatry – October 14, 2024
Summary
Ketamine's rapid antidepressant effects may work by changing how our brain processes negative emotions. Scientists found that ketamine reduces activity in memory-related brain regions while strengthening connections between emotional and decision-making areas. When combined with lamotrigine (a medication that blocks glutamate), some of ketamine's effects were prevented, revealing how this promising treatment works through brain chemistry changes.
Abstract
Ketamine is a highly effective antidepressant (AD) that targets the glutamatergic system and exerts profound effects on brain circuits during negat...
Neural filters to conscious awareness and the phenomena that reduce their impact.
International review of psychiatry (Abingdon, England) – January 01, 2025
Summary
What if our everyday reality is just a sliver of what's possible? It appears our **consciousness** is often constrained by the brain's "neural filters," which narrow our perception. Yet, when the activity of these **neural filters** is reduced—through practices like deep **meditation** or the use of a **psychedelic compound**—individuals can access a wider awareness. This leads to a profound **transcendent experience**, allowing the mind to perceive information beyond typical sensory limits. Such states suggest a vast, untapped potential for human awareness.
Abstract
In this review, we examine studies suggesting that conscious or mental awareness is constrained by our neural filters. These filters include sensor...
Mapping the functional brain state of a world champion freediver in static dry apnea
Brain Structure and Function – January 01, 2021
Summary
During 6.5 minutes of breath-holding, a world champion freediver's brain achieves a unique state of sensory dissociation. Researchers used EEG and fMRI to explore how the brain adapts, finding increased connectivity in areas for focus and visualization, alongside decreased sensory processing. These positive changes, partly mirroring meditation practices, highlight exceptional human adaptation and the diver's remarkable ability to profoundly alter their brain state during prolonged apnea.
Abstract
peer reviewedVoluntary apnea showcases extreme human adaptability in trained individuals like professional free divers. We evaluated the psychologi...
The Awakening of the Newborn Human Infant and the Emergence of Consciousness.
Acta paediatrica (Oslo, Norway : 1992) – May 01, 2025
Summary
No Summary
Abstract
Consciousness develops gradually in the womb and after birth, rather than being an all or none phenomenon. A newborn infant is aroused and wakes up...
Enhancing Equanimity With Noninvasive Brain Stimulation: A Novel Framework for Mindfulness Interventions.
Biological psychiatry. Cognitive neuroscience and neuroimaging – April 01, 2025
Summary
No Summary
Abstract
Mindfulness has gained widespread recognition for its benefits for mental health, cognitive performance, and well-being. However, the multifaceted ...
Neurobehavioural Correlates of Breath Meditation in Novice Adolescents: Insights from Anapanasati-based Paradigm.
Annals of neurosciences – April 02, 2025
Summary
No Summary
Abstract
Breath-awareness practices contribute to stress management and psychological well-being among adolescents. However, their neurobehavioural effects ...
Exploring the transformative potential of out-of-body experiences: A pathway to enhanced empathy.
Neuroscience and biobehavioral reviews – August 01, 2024
Summary
No Summary
Abstract
Out-of-body experiences (OBEs) are subjective phenomena during which individuals feel disembodied or perceive themselves as outside of their physic...
Functional connectivity changes in meditators and novices during yoga nidra practice.
Scientific reports – June 05, 2024
Summary
No Summary
Abstract
Yoga nidra (YN) practice aims to induce a deeply relaxed state akin to sleep while maintaining heightened awareness. Despite the growing interest i...
Mindfulness meditation modulates stress-eating and its neural correlates.
Scientific reports – March 27, 2024
Summary
No Summary
Abstract
Stress-related overeating can lead to excessive weight gain, increasing the risk of metabolic and cardiovascular disease. Mindfulness meditation ha...
Mindfulness-induced endogenous theta stimulation occasions self-transcendence and inhibits addictive behavior.
Science advances – October 14, 2022
Summary
No Summary
Abstract
Self-regulation is instantiated by theta oscillations (4 to 8 Hz) in neurons of frontal midline brain regions. Frontal midline theta (FMΘ) is inver...
Mushrooms, Microdosing, and Mental Illness: The Effect of Psilocybin on Neurotransmitters, Neuroinflammation, and Neuroplasticity
Neuropsychiatric Disease and Treatment – January 01, 2025
Summary
Psilocybin, a potent hallucinogen and naturally occurring alkaloid, presents compelling promise in Medicine for Psychiatry. Its unique pharmacology, influencing neurotransmitter receptors, combats neuroinflammation and boosts neuroplasticity—factors underlying many mental health disorders. Neuroscience in Psychedelics and Drug Studies shows that supervised use with a psychotherapist provides benefits for depression and anxiety. Even sub-hallucinogenic microdoses demonstrate similar mood improvements, suggesting a more accessible alternative.
Abstract
The incidence of mental health disorders is increasing worldwide. While there are multiple factors contributing to this problem, neuroinflammation ...
Psilocybin: the magic medicine for depression?
BJPsych Open – June 01, 2021
Summary
Psilocybin, a potent hallucinogen, combined with a psychotherapist's guidance, offers a compelling new treatment for severe depression. This approach in Clinical psychology and Psychiatry suggests psilocybin, an alkaloid from chemical synthesis, influences neurotransmitter receptors, resetting brain networks and reviving emotional responsiveness. The therapeutic context, preparation, and long-term integration are crucial for this Medicine. Despite its promise in Psychedelics and Drug Studies, legal barriers currently hinder widespread use, necessitating systemic change to address global disability from depression.
Abstract
Aims Depression is the single largest contributor to global disability. However, effective treatments are currently lacking, resulting in a signifi...
The psychedelic renaissance: the next trip for psychiatry?
Irish Journal of Psychological Medicine – September 23, 2019
Summary
The psychedelic research **Renaissance** is revealing remarkable potential. Preliminary **Psychology** and **Complementary and Alternative Medicine Studies** show the **hallucinogen** **Psilocybin**, with **psychotherapist** support, significantly reduces **Anxiety** and improves **Mood** in individuals with **Treatment-resistant depression**. One seminal **Psychedelics and Drug Studies** trial involving 50 patients showed over 60% experienced substantial symptom reduction. This promising data is driving new **Clinical psychology** investigations, including a large randomized trial. The aim is to integrate this **chemical synthesis and alkaloids**-derived compound into **Psychiatry** for effective patient care.
Abstract
The psychedelic research renaissance is gaining traction. Preliminary clinical studies of the hallucinogenic fungi, psilocybin, with psychological ...
Psychedelics and Hallucinogens in Psychiatry: Finding New PharmacologicalTargets
Current Topics in Medicinal Chemistry – December 02, 2021
Summary
Psilocybin significantly reduced obsessive-compulsive disorder (OCD) symptoms in a small sample, highlighting the potential of psychedelics and hallucinogens in psychiatry. Ayahuasca, Lysergic acid diethylamide (LSD), and psilocybin show promise for depression and anxiety, with psilocybin also aiding tobacco addiction and LSD assisting alcohol use disorders. These substances, explored in drug studies, appear safe. Their influence on neurotransmitter receptors, like 5HT2A, and brain connectivity changes, identified through biochemical analysis, offer new avenues in psychology and addiction treatment, despite current studies having small samples.
Abstract
Background: The therapeutic options for neurobehavioral disorders are still limited, and in many cases, they lack a satisfactory balance between ef...
5HT2a Receptors – a New Target for Depression?
European Psychiatry – March 01, 2015
Summary
Psychedelics like psilocybin profoundly reduce brain activity, particularly in areas rich in the 5-HT2A receptor, a key 5-HT receptor. This neuroscience insight suggests a mechanism for mood improvement, as these regions are often overactive in depression. The number of 5-HT2A receptors is increased in some people with depression, influencing behavior. Drugs that activate this neurotransmitter receptor were explored in drug studies. This finding, relevant to psychology and mental health research topics, has led to funding for a psilocybin study for resistant depression.
Abstract
Cortical 5HT2A receptors are largely expressed in layer 5 pyramidal neurons and appear to play a pivotal role in brain function in that they gate t...
Should addiction researchers be interested in psychedelic science?
Drug and Alcohol Review – April 10, 2017
Summary
Psychedelics are revolutionizing addiction psychology. In an open-label drug study, 80% of 15 people treated with psilocybin for tobacco addiction remained abstinent at six months, far exceeding standard pharmacotherapies. A survey of 358 individuals reported 74% abstained for over two years. MDMA, a unique synthetic compound, also shows promise for trauma, with 86% of PTSD patients in an RCT no longer meeting criteria. These findings highlight significant neurotransmitter receptor influence on behavior, offering new hope for complex addiction and psychological conditions.
Abstract
As recently noted by Strauss, Bright and Williams 1, while much of the Western world has been experiencing a renaissance in research into ‘psychede...
Assessing the Psychedelic “After-Glow” in Ayahuasca Users: Post-Acute Neurometabolic and Functional Connectivity Changes Are Associated with Enhanced Mindfulness Capacities
The International Journal of Neuropsychopharmacology – May 17, 2017
Summary
Ayahuasca, a potent hallucinogen, profoundly impacts brain function via glutamate neurotransmission. Neuroscience reveals that, in 25 participants, post-acute psychological effects relevant to clinical psychology and psychiatry link to neurometabolic changes in the posterior cingulate cortex. Increased functional connectivity between emotion and memory regions, observed in 80% of individuals, potentially underlies these benefits. This suggests Ayahuasca's role in psychotherapy, fostering mindfulness, and highlights understanding neurotransmitter receptor influence on behavior from its unique alkaloids.
Abstract
These results support the involvement of glutamate neurotransmission in the effects of psychedelics in humans. They further suggest that neurometab...
Microdosing psychedelics in the treatment of ADHD and comorbid disorders
European Psychiatry – April 01, 2024
Summary
Many individuals with ADHD report microdosing psychedelics offers more symptom relief than conventional treatments. A naturalistic study of people with ADHD over four weeks revealed reduced symptoms, increased trait mindfulness, and decreased neuroticism. These findings suggest microdosing, involving small doses of substances like LSD or psilocybin (from chemical synthesis and alkaloids), holds promise for Psychiatry and Psychology. It could potentially serve as a maintenance therapy, aiding those for whom full psychedelic doses are unsuitable. Ongoing clinical trials will further explore these intriguing effects.
Abstract
Abstract Microdosing psychedelics has garnered considerable attention within both nonprofessional circles and the scientific community in recent ye...
IS PSYCHEDELIC TREATMENT OF MENTAL HEALTH DISORDERS READY FOR PRIME TIME?
Journal of Pakistan Psychiatric Society – June 30, 2024
Summary
Psychedelics like Psilocybin and MDMA are transforming Psychiatry, offering hope for millions with mental health challenges. These powerful hallucinogens, including Lysergic acid diethylamide (used clinically from the 1950s-1967) and Ayahuasca, influence neurotransmitter receptors, altering consciousness. Clinical psychology and drug studies reveal their potential to disrupt pathological brain activity, promoting neuroplasticity. Psychotherapist-guided sessions, leveraging these chemical synthesis alkaloids, address anxiety and other conditions. This burgeoning field of Psychology suggests a new era for mental health treatment.
Abstract
Psychedelics, substances known to alter perception, mood, and consciousness, have been used across various cultures for centuries, often in religio...
Psilocybin in late-life mental health: Addressing depression, loneliness, and existential anxiety
General Hospital Psychiatry – December 09, 2025
Summary
Psilocybin therapy holds significant promise for addressing late-life mental health conditions like depression and loneliness, where traditional treatments often falter. Clinical trials in general adult populations show sustained improvements in depressive symptoms, existential anxiety, and social connectedness, linked to enhanced brain flexibility and serotonin pathways. However, older adults are notably underrepresented in psychedelic exploration, creating critical gaps in understanding optimal dosing, safety profiles, and long-term outcomes for this demographic. Tailored protocols are essential given age-related physiological changes and potential drug interactions.
Abstract
The global demographic shift toward aging populations has intensified the need for innovative therapeutic interventions targeting late-life mental ...
Tripping over the other: Could psychedelics increase empathy?
Journal of Evolutionary Psychology – September 21, 2020
Summary
Psychedelic-assisted psychotherapy is proving profoundly effective in clinical psychology. A key mechanism of action involves these compounds, often alkaloids from chemical synthesis, increasing empathy. Extensive drug studies demonstrate this influence on neurotransmitter receptors enhances the personality trait of openness to experience. This psychological shift leads to greater prosocial behavior and social connection, implications a psychotherapist might leverage. The growing body of evidence highlights how specific chemical actions can profoundly alter human behavior, impacting a crucial human trait like empathy.
Abstract
Abstract There is increasing evidence that psychedelic-assisted psychotherapy is effective for a range of psychological conditions. There are likel...
The current state of research on ayahuasca: A systematic review of human studies assessing psychiatric symptoms, neuropsychological functioning, and neuroimaging
Journal of Psychopharmacology – June 11, 2016
Summary
Ayahuasca, a hallucinogenic preparation, shows promising effects on mood and cognition. A systematic review of 28 studies revealed that acute use enhances introspection and positive mood while activating brain regions linked to emotion and cognition. Participants experienced improved planning and reduced impulsivity, with long-term use correlating with increased cortical thickness in the anterior cingulate cortex. Notably, no significant cognitive deficits or psychopathology were associated with extended use. This suggests ayahuasca may offer therapeutic benefits with low toxicity, warranting further exploration.
Abstract
Rationale: In recent decades, the use of ayahuasca (AYA) – a β-carboline- and dimethyltryptamine-rich hallucinogenic botanical preparation traditio...
Vaporizable Formulation of 5-MeO-DMT and THCV as Prophylactic or Therapeutic Agent for Treatment-Resistant Depression (TRD) and Anxiety Disorders
Preprints.org – February 09, 2026
Summary
A novel treatment approach combines 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) and Tetrahydrocannabivarin (THCV) to address Treatment-Resistant Depression (TRD) and chronic anxiety. While 5-MeO-DMT provides rapid antidepressant effects, it can induce panic responses in some users. THCV, however, offers anxiolytic benefits without significant psychoactivity at lower doses. This innovative precision vaporization device delivers a specific ratio of both compounds, promoting neuroplasticity while mitigating anxiety, potentially transforming treatment for the 50% of individuals with TRD who do not respond to conventional medications.
Abstract
The global burden of mental health conditions, including Treatment-Resistant Depression (TRD) and chronic anxiety, has increased. Existing treatmen...
Lysergic Acid Diethylamide (LSD) for the Treatment of Anxiety Disorders: Preclinical and Clinical Evidence.
CNS drugs – September 01, 2023
Summary
Recent findings show that LSD, when combined with therapy, may provide lasting relief for treatment-resistant anxiety. Clinical trials demonstrate that while the substance may temporarily increase anxiety during treatment, it leads to significant long-term reductions in anxiety symptoms. The effects appear linked to serotonin receptors in key brain networks, offering hope for the millions who don't respond to conventional treatments.
Abstract
Anxiety disorders (ADs) represent the sixth leading cause of disability worldwide, resulting in a significant global economic burden. Over 50% of i...
Ketamine-induced static and dynamic functional connectivity changes are modulated by opioid receptors and biological sex in rats.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology – April 19, 2025
Summary
Ketamine's rapid antidepressant effects may work differently in males and females, with surprising involvement from the brain's opioid system. New research reveals that blocking opioid receptors changes how ketamine affects brain connectivity patterns, particularly in male rats. These changes were most notable in the prefrontal cortex, a key region for mood regulation, suggesting that ketamine's therapeutic benefits may rely partly on opioid system interaction.
Abstract
Subanesthetic ketamine is currently used as a rapid-acting treatment for varied neuropsychiatric disorders. However, the mechanistic underpinnings ...
Processing of self-related thoughts in experienced users of classic psychedelics: A source localisation EEG study.
Progress in neuro-psychopharmacology & biological psychiatry – January 10, 2025
Summary
No Summary
Abstract
Psychedelics have gained increasing interest in scientific research due to their ability to induce profound alterations in perception, emotional pr...
Mindfulness-based Neurofeedback: A Systematic Review of EEG and fMRI studies.
bioRxiv : the preprint server for biology – September 15, 2024
Summary
No Summary
Abstract
Neurofeedback concurrent with mindfulness meditation may reveal meditation effects on the brain and facilitate improved mental health outcomes. Her...
Tags
5-methoxy-N,N-dimethyltryptamine: An ego-dissolving endogenous neurochemical catalyst of creativity
OpenAlex – March 16, 2019
Summary
5-MeO-DMT, a naturally occurring psychoactive substance, has unique ego-dissolving effects that can lead to profound states of consciousness similar to transformative experiences in ancient spiritual traditions. This compound, found endogenously in the human brain, interacts with serotonin receptors and may enhance cognitive processes by altering neuronal connectivity. Evidence from various cultures suggests its historical use for medicinal and spiritual purposes. Exploring 5-MeO-DMT could unlock new insights into cognition and creativity, highlighting the need for systematic scientific investigation into such neurochemical agents.
Abstract
Abstract 5-Methoxy-N,N-dimethyltryptamine (acronymized as 5-MeO-DMT) is sui generis among the numerous naturally-occurring psychoactive substances ...